Following the publication of our article [1] we noticed an error within Additional file 2: Comparison of patient baseline characteristics by condition. The column headings 'Control' and 'Intervention' are incorrectly positioned in the table and should be switched.
The table should therefore appear as shown in Table 1 in this correction.
Table 1.
Comparison of patient baseline characteristics by condition
| Condition Group | Characteristic | Control n (%) | Intervention n (%) | Total n (%) | |
| Diabetes | N = 785 | N = 1182 | N = 1967 | ||
| Male | 432 (55.0) | 651 (55.1) | 1083 (55.1) | ||
| Age (years) | Median (IQ range) | 67.0 (59.0–74.0) | 66.0 (58.0–73.0) | 66.0 (59.0–73.0) | |
| Aboriginal and Torres Strait Islander | Yes | 4 (0.5) | 23 (1.9) | 27 (1.4) | |
| No | 723 (92.1) | 1036 (87.6) | 1759 (89.4) | ||
| Missing | 58 (7.4) | 123 (10.4) | 181 (9.2) | ||
| BMI | Underweight | 5 (0.6) | 3 (0.3) | 8 (0.4) | |
| Normal | 121 (15.4) | 181 (15.3) | 302 (15.4) | ||
| Overweight | 243 (31.0) | 386 (32.7) | 629 (32.0) | ||
| Obese | 334 (42.5) | 464 (39.3) | 798 (40.6) | ||
| Missing | 82 (10.4) | 148 (12.5) | 230 (11.7) | ||
| HbA1c % | Median (IQ range) | 7.1 (6.3–8.0) | 6.9 (6.2–7.7) | 7.0 (6.3–7.8) | |
| Missing | 64 (8.2) | 90 (7.6) | 154 (7.8) | ||
| Diabetes management: | |||||
| Dietary control | Yes | 446 (56.8) | 604 (51.1) | 1050 (53.4) | |
| No | 309 (39.4) | 503 (42.6) | 812 (41.3) | ||
| Missing | 30 (3.8) | 75 (6.3) | 105 (5.3) | ||
| Insulin | Yes | 145 (18.5) | 204 (17.3) | 349 (17.7) | |
| No | 610 (77.7) | 903 (76.4) | 1513 (76.9) | ||
| Missing | 30 (3.8) | 75 (6.3) | 105 (5.3) | ||
| Prescription tablets | Yes | 541 (68.9) | 729 (61.7) | 1270 (64.6) | |
| No | 214 (27.3) | 378 (32.0) | 592 (30.1) | ||
| Missing | 30 (3.8) | 75 (6.3) | 105 (5.3) | ||
| Years since first diagnosed | < 1 year | 39 (5.0) | 67 (5.7) | 106 (5.4) | |
| 1–5 years | 256 (32.6) | 403 (34.1) | 659 (33.5) | ||
| 6–10 years | 201 (25.6) | 235 (19.9) | 436 (22.2) | ||
| > 10 years | 230 (29.3) | 311 (26.3) | 541 (27.5) | ||
| Missing | 59 (7.5) | 166 (14.0) | 225 (11.4) | ||
| Hyperlipidaemia | N = 1463 | N = 2356 | N = 3819 | ||
| Male | 753 (51.5) | 1277 (54.2) | 2030 (53.2) | ||
| Age (years) | Median (IQ range) | 68.0 (60.0–74.0) | 66.0 (58.0–74.0) | 66.0 (59.0–74.0) | |
| Aboriginal and Torres Strait Islander | Yes | 9 (0.6) | 26 (1.1) | 35 (0.9) | |
| No | 1342 (91.7) | 2102 (89.2) | 3444 (90.2) | ||
| Missing | 112 (7.7) | 228 (9.7) | 340 (8.9) | ||
| Index of Relative Socio-Economic Disadvantage | 1st quartile | 251 (17.2) | 575 (24.4) | 826 (21.6) | |
| 2nd quartile | 476 (32.5) | 756 (32.1) | 1232 (32.3) | ||
| 3rd quartile | 390 (26.7) | 663 (28.1) | 1053 (27.6) | ||
| 4th quartile | 346 (23.7) | 362 (15.4) | 708 (18.5) | ||
| Co-morbid conditions: | |||||
| Known heart disease | Yes | 540 (36.9) | 812 (34.5) | 1352 (35.4) | |
| No | 869 (59.4) | 1398 (59.3) | 2267 (59.4) | ||
| Missing | 54 (3.7) | 146 (6.2) | 200 (5.2) | ||
| Diabetes | 509 (34.8) | 853 (36.2) | 1362 (35.7) | ||
| Smoking status | Current | 103 (7.0) | 201 (8.5) | 304 (8.0) | |
| Ex-smoker | 644 (44.0) | 1001 (42.5) | 1645 (43.1) | ||
| Never smoked | 654 (44.7) | 990 (42.0) | 1644 (43.0) | ||
| Missing | 62 (4.2) | 164 (7.0) | 226 (5.9) | ||
| Total cholesterol | Median (IQ range) | 4.7 (4.0–5.4) | 4.6 (4.0–5.4) | 4.7 (4.0–5.4) | |
| Missing | 99 (6.8) | 186 (7.9) | 285 (7.5) | ||
| Triglyceride | Median (IQ range) | 1.6 (1.1–2.2) | 1.6 (1.2–2.2) | 1.6 (1.2–2.2) | |
| Missing | 185 (12.6) | 204 (8.7) | 389 (10.2) | ||
| HDL-C | Median (IQ range) | 1.3 (1.1–1.6) | 1.3 (1.1–1.5) | 1.3 (1.1–1.6) | |
| Missing | 239 (16.3) | 515 (21.9) | 754 (19.7) | ||
| Anticoagulant therapy | N = 372 | N = 572 | N = 944 | ||
| Male | 217 (58.3) | 326 (57.0) | 543 (57.5) | ||
| Age (years) | Median (IQ range) | 73.0 (66.0–79.0) | 73.0 (65.0–78.0) | 73.0 (65.0–79.0) | |
| BMI | Underweight | 7 (1.9) | 5 (0.9) | 12 (1.3) | |
| Normal | 90 (24.2) | 165 (28.8) | 255 (27.0) | ||
| Overweight | 130 (34.9) | 190 (33.2) | 320 (33.9) | ||
| Obese | 111 (29.8) | 132 (23.1) | 243 (25.7) | ||
| Missing | 34 (9.1) | 80 (14.0) | 114 (12.1) | ||
| Multiple co-morbidities | Yes | 170 (45.7) | 285 (49.8) | 455 (48.2) | |
| No | 186 (50.0) | 259 (45.3) | 445 (47.1) | ||
| Missing | 16 (4.3) | 28 (4.9) | 44 (4.7) | ||
| INR | Below target range | 73 (19.6) | 115 (20.1) | 188 (19.9) | |
| Within target range | 197 (53.0) | 316 (55.2) | 513 (54.3) | ||
| Above target range | 37 (9.9) | 63 (11.0) | 100 (10.6) | ||
| Missing | 65 (17.5) | 78 (13.6) | 143 (15.1) |
Contributor Information
Caroline Laurence, Email: caroline.laurence@adelaide.edu.au.
Angela Gialamas, Email: angela.gialamas@adelaide.edu.au.
Lisa Yelland, Email: lisa.yelland@adelaide.edu.au.
Tanya Bubner, Email: tanya.bubner@adelaide.edu.au.
Philip Ryan, Email: philip.ryan@adelaide.edu.au.
Kristyn Willson, Email: kristyn.willson@adelaide.edu.au.
Briony Glastonbury, Email: bglastonbury@eye.usyd.edu.au.
Janice Gill, Email: jan.gill@rcpaqap.com.au.
Mark Shephard, Email: mark.shephard@flinders.edu.au.
Justin Beilby, Email: Justin.beilby@adelaide.edu.au.
for members of the PoCT Trial Management Committee, Email: caroline.laurence@adelaide.edu.au.
References
- Laurence C, Gialamas A, Yelland L, Bubner T, Ryan P, Willson K, Glastonbury B, Gill J, Shepard M, Beilby J, for members of the PoCT Trial Management Committee A pragmatic cluster randomised controlled trial to evaluate the safety, clinical effectiveness, cost effectiveness and satisfaction with point of care testing in a general practice setting – rationale, design and baseline characteristics. Trials. 2008;9:50. doi: 10.1186/1745-6215-9-50. [DOI] [PMC free article] [PubMed] [Google Scholar]